A Preview of the 2013 ASH Annual Meeting
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.
Abstract 69
Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy
- Research in this area has come to fruition in the last year in ALL
- This genetically manipulated T cell therapy can be used in patients with ALL who have failed other therapies
- This therapy could provide a ‘bridge’ to life-saving bone marrow transplant
Abstract 852
Combining Ibrutinib With R-CHOP: Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell NHL
- Ibrutinib has been used in a variety of B-cell tumors
- Results from this study are particularly promising because response rates were higher than what would be normally seen in this space
<<<
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
